Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

NCT06427395 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: Saroglitazar Magnesium 1 mg

Sponsor

Zydus Therapeutics Inc.